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S U M M A R Y
Objective: To estimate and compare disease burden attributable to six gastrointestinal pathogens
(norovirus, rotavirus, Campylobacter, non-typhoidal Salmonella, Giardia, and Cryptosporidium) in
Australia, 2010.
Methods: We estimated the number of acute gastroenteritis (AGE) cases and deaths, disability-adjusted
life years (DALYs), and DALY/case for each pathogen. We included AGE cases that did not require medical
care. Sequelae were included for Campylobacter (Guillain–Barre´ syndrome, reactive arthritis (ReA),
irritable bowel syndrome (IBS)) and Salmonella (ReA, IBS).
Results: We estimated 16 626 069 AGE cases in Australia in 2010 (population 22 million). Of the
pathogens studied, most AGE cases were attributed to norovirus (2 180 145), Campylobacter (774 003),
and Giardia (614 740). Salmonella caused the fewest AGE cases (71 255) but the most AGE deaths (90).
The DALY burden was greatest for Campylobacter (18 222 DALYs) and Salmonella (3856 DALYs),
followed by the viral and protozoal pathogens. The average DALY/case was greatest for Salmonella
(54.1 DALY/1000 cases), followed by Campylobacter (23.5 DALY/1000 cases).
Conclusions: The pathogen causing the greatest disease burden varied according to the metric used,
however DALYs are considered most useful given the incorporation of morbidity, mortality, and
sequelae. These results can be used to prioritize public health interventions toward Salmonella and
Campylobacter infections and to measure the impact of these interventions.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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Acute gastroenteritis (AGE) results in signiﬁcant morbidity and
mortality in Australia and worldwide.1,2 Estimating AGE disease
burden is an important element of estimating food-borne disease
burden, a worldwide public health priority.1,3 Disease burden can be
measured in multiple ways, including number of cases, number of
deaths, and more sophisticated metrics such as disability-adjusted
life years (DALYs). The DALY takes into account disease mortality
(years of life lost, YLL) and morbidity (years lost due to disability,
YLD), where DALY = YLL + YLD. Speciﬁcally, DALYs incorporate
information on the incident number of disease cases, illness
duration, disease severity (disability weight), incident number of
deaths, and life expectancy at age of death. Differing health
outcomes can be incorporated into DALY disease models, including
disease sequelae. In high-income countries where case fatality rates* Corresponding author. Tel.: +61 3 9903 0605; fax: +61 3 9903 0556.
E-mail address: Katherine.Gibney@monash.edu (K.B. Gibney).
http://dx.doi.org/10.1016/j.ijid.2014.08.006
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).of AGE are low, sequelae to Campylobacter and Salmonella infection
have been reported to cause greater DALY burden than the AGE
itself.4,5 One DALY equates to one lost year of ‘healthy’ life and the
metric quantiﬁes the gap between a population’s current health
status and an ideal where everyone lives to advanced age in perfect
health. In addition to using the DALY to quantify the population
disease burden, the average DALY/case can indicate the relative
severity of disease caused by different pathogens.
We estimated the disease burden of six common gastrointesti-
nal pathogens in Australia for the year 2010 and compared the
number of cases, number of deaths, DALYs, and average DALY/case
for each pathogen. We examined the two most common pathogens
for high-income countries in each of the three major AGE pathogen
groups:4,6,7 viruses (rotavirus and norovirus), protozoa (Crypto-
sporidium and Giardia), and bacteria (Salmonella and Campylo-
bacter). Comparing our results to international studies highlights
the impact of environmental conditions, risk factors, and preven-
tive measures on disease burden, with differences in disease
burden estimates from speciﬁc AGE pathogens even between high-
income countries; for example the incidence of Campylobacterciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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USA.8 Therefore, there is the need for country-speciﬁc disease
burden estimates. These results can be used to assess the burden of
AGE illnesses caused by different pathogens and pathogen groups,
to inform appropriate public health responses to speciﬁc patho-
gens and pathogen groups, and to rationalize optimal targets for
disease prevention.
2. Methods
2.1. Overview
We ﬁrst estimated the total number of all-cause AGE cases in
Australia in 2010 and then the number of all-cause AGE cases in
four severity categories based on the requirement for medical care:
fatal, hospitalized (inpatient medical care), outpatient (outpatient
medical care), and mild (no medical care). Next we estimated the
number of AGE cases attributable to each study pathogen
(norovirus, rotavirus, Campylobacter, non-typhoidal Salmonella,
Giardia, and Cryptosporidium) in terms of total AGE cases as well
as fatal, hospitalized, outpatient, and mild AGE cases (Figure 1). We
then estimated the number of cases of sequelae attributable to the
two bacterial pathogens and the proportion in each severity
category. Sequelae were included for Campylobacter (Guillain–
Barre´ syndrome, reactive arthritis (ReA), irritable bowel syndrome
(IBS)) and Salmonella (ReA, IBS). Finally we estimated disease
duration, disability weight, and average life expectancy at age of
death in order to calculate the DALYs and DALY/case (Figure 2).
2.2. Population included
Our estimates were for all AGE cases, including those not
requiring medical care, for the entire Australian population. For
rotavirus, some previous DALY estimates have used a population of
unvaccinated children <5 years of age.9 However, because
rotavirus cases are not conﬁned to young children and rotavirus
vaccine was added to Australia’s National Immunisation Pro-
gramme in July 2007,10,11 we calculated the rotavirus burden in
three Australian populations: (1) entire population, unvaccinated;
(2) <5 years of age, unvaccinated; and (3) <5 years of age,
vaccinated. Due to incomplete data on the impact of a partially
vaccinated population, when comparing disease burden caused by  Total AG E  Fatal AG E  Hosp ita 
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Figure 1. Outline of methods used to estimate all-cause and pathogen-speciﬁthe six AGE pathogens we used our estimates of rotavirus in the
entire (unvaccinated) population.
2.3. Selecting data sources used in these DALY models
We used a combination of Australian administrative data (e.g.,
Australian notiﬁcation/hospitalization/mortality data) and pub-
lished and unpublished studies in our disease burden calculations.
We obtained Australian administrative data through the websites
of the relevant agencies and through formal data requests made to
these agencies. Additionally, we submitted data requests to access
unpublished data from OzFoodNet (a federally funded health
network to enhance the surveillance of food-borne diseases in
Australia) and the University of Sydney’s ‘Bettering the Evaluation
And Care of Health’ (BEACH) program, which collects information
from Australian general practitioners (GPs).
To identify the published studies used in this report, we
performed a literature review in PubMed using a combination of
the following terms: ‘gastroenteritis’, ‘community’, ‘hospital’,
‘deaths’, ‘epidemiology’, ‘Australia’, ‘norovirus’, ‘rotavirus’, ‘Cam-
pylobacter’, ‘Salmonella’, ‘Giardia’, and ‘Cryptosporidium’. We
reviewed the titles of articles identiﬁed, and then based on
perceived relevance we reviewed the abstracts before sourcing the
full article. We reviewed the reference lists of articles to identify
further relevant publications and reports. Only publications
available in English were considered. The main literature review
was performed in 2012; this was supplemented by targeted
literature reviews until models were ﬁnalized. We selected data
sources and studies based on certain criteria, including: (1) Study
quality – size, duration, scientiﬁc rigor. These were the most
important criteria for selecting studies to include in our DALY
models. (2) Location – where possible we used Australian data, but
if necessary we used data from other high-income countries (e.g.,
New Zealand, Europe, North America, and Japan). (3) Recency. (4)
Internal consistency – where possible we used the same data
sources for multiple pathogens. However, if the estimates for a
particular pathogen deviated from other published estimates, we
used judgement to choose an alternate data source to determine
the most likely estimate. (5) Disease severity information, e.g.,
outpatient medical care, hospitalized, etc. (6) Age-group speciﬁc
information – where available we included age-group speciﬁc data
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Figure 2. Data points required to calculate disability-adjusted life years (DALY) for acute gastroenteritis (AGE) pathogens (ReA, reactive arthritis; GBS, Guillain–Barre´
syndrome).
K.B. Gibney et al. / International Journal of Infectious Diseases 28 (2014) 176–1851782.4. Estimating AGE case numbers
2.4.1. Total all-cause infectious AGE cases
We applied age-weighted AGE rates from the national
gastroenteritis survey NGSII-2008 study to the 2010 Australian
population.12 The NGSII-2008 study was a national cross-sectional
telephone survey of 7578 participants conducted over 12 months
in 2008–2009 in which infectious gastroenteritis was deﬁned as at
least three loose stools or two vomits in 24 h, in the absence of an
identiﬁed non-infectious cause.13 The full methodology of that
study is a repeat of the earlier national gastroenteritis survey.2
2.4.2. All-cause AGE cases in each severity level
For each severity category we applied the estimated annual
incidence of disease or death to the 2010 Australian population.12
For fatal AGE cases (all-cause), we determined average annual
deaths with AGE as an underlying cause (International Classiﬁca-
tion of Diseases, 10th revision (ICD-10) codes A00–09) from the
National Mortality Database (NMD, 1998–2007).14
For hospitalized AGE cases (all-cause), we combined the
estimated number of AGE hospitalizations with half the estimated
number of non-admitted emergency department (ED) encounters
for AGE. Age-group speciﬁc hospitalization rates with a principal
diagnosis of AGE (ICD-10 codes A00–A09) were obtained from the
National Hospital Morbidity Database (1998/99–2007/08).15 Total
ED visits in 2010 was reported by the Australian Institute of Health
and Welfare;16 the proportion that were non-admitted ED
encounters for AGE was obtained from state health departments
(Queensland 2001/02–2009/10, New South Wales 1996/97–2009/
10, Victoria 1999/2000–2009/10, and South Australia 2007/08–
2009/10). We split the non-admitted ED encounters for AGE
equally between the outpatient and hospitalized AGE categories, as
we judged that some people attend ED with AGE because illness
occurs when GP practices are closed (i.e., more like outpatient
cases), while others go to the ED because they have severe
symptoms (i.e., require intravenous ﬂuid).
For outpatient AGE cases (all-cause), we combined GP visits for
AGE with half the non-admitted ED encounters for AGE (see
above). Total GP encounters for 2010 were obtained fromMedicare, and the age-speciﬁc proportions attributable to AGE
were derived from BEACH study data (2006–2011).17,18 The BEACH
study has been run by the University of Sydney since 1998. Each
year, a random sample of 1000 GPs across Australia is surveyed
with each recording details of 100 consecutive consultations.
With regard to mild AGE cases (all-cause), to account for AGE
cases not requiring medical care and to ensure internal consistency
in our disease models, mild AGE cases were estimated by
subtracting fatal, hospitalized, and outpatient AGE cases from
total AGE cases.
2.4.3. Pathogen-speciﬁc estimates of AGE cases and deaths
For total, hospitalized, and outpatient AGE cases (pathogen-
speciﬁc), the proportions of all-cause AGE cases attributable to
each pathogen (the pathogen fractions) were derived from studies
listed in Table 1 and applied to the all-cause AGE estimate of each
severity category. For total AGE cases we used the pathogen
fraction from a population-based study from the Netherlands (the
Sensor study) for all study pathogens other than Campylobacter,19
for which we used the pathogen fraction from a British study (the
IID2 study),20 as this result was more consistent with other studies
reviewed.21–23 Similarly, for outpatient AGE cases we used the
pathogen fraction from a GP-based study from the Netherlands
(the NIVEL study) for the rotavirus, Cryptosporidium, Salmonella,
and Campylobacter AGE estimates,24 but the norovirus fraction
from the IID2 study and the Giardia fraction from an Icelandic
study (Hilmarsdo´ttir 2012),20,25 as these were more consistent
with the pathogen fraction reported in other studies reviewed.26–
31 As hospital-based studies were generally restrictive in terms of
pathogens studied and age-groups included (paediatric vs. adult), a
number of studies were used to estimate hospitalized AGE cases
for each pathogen.70–79
With regard to fatal AGE cases (pathogen-speciﬁc), because of
concerns about signiﬁcant under-reporting of AGE deaths in the
NMD, we used a combination of approaches to estimate AGE
fatalities by different pathogens. For the protozoal study pathogens
(Cryptosporidium and Giardia) we used vital registration data
directly from the NMD (ICD-10 codes A00–A09, 1998–2007).14
This is because, consistent with NMD data, published studies
Table 1
Data sources used to calculate number of cases and duration of illness for acute gastroenteritis and sequelae—Australia, 2010
Acute gastroenteritis Number of cases Duration
Total Outpatient Hospitalizeda Mild Outpatient Hospitalized
Norovirus de Wit 200119 Tam 201120 Jansen 200870
Lorrot 201171
Patel 200872
Sinclair 200523 OzFoodNet outbreak registry45 Kemmeren 200649
Rotavirus de Wit 200119 de Wit 200124 Jansen 200870
Lopman 201173
Carlin 199874
Kemmeren 200649 Kemmeren 200649 de Wit 200047
Cryptosporidium de Wit 200119 de Wit 200124 Tzipori 198375 Sinclair 200523 Sinclair 200523 Robertson 200146
Giardia de Wit 200119 Hilmarsdo´ttir 201225 Jansen 200870
Essers 200076
Nash 198777 Homan 201250 Nyga˚rd 200678
Campylobacter Tam 201120 de Wit 200124 Jansen 200870
Barnes 199879
Kemmeren 200649 Kemmeren 200649 Kemmeren 200649
Salmonella de Wit 200119 de Wit 200124 Jansen 200870
Barnes 199879
Sinclair 200523 Food Standards Agency 201121 McPherson 200648
Sequelae (pathogen) Number of cases Duration
Total In each severity group
GBS (Campylobacter) Poropatich 201040
Hankey 198739
Mangen 200441 Havelaar 200022
ReA (Campylobacter) Hannu 200242 Hannu 200242 Mangen 200441
ReA (Salmonella) Tuompo 201343 Tuompo 201343 Mangen 200441
IBS (Campylobacter,
Salmonella)
Haagsma 201044 - Haagsma 201044
GBS, Guillain–Barre´ syndrome; ReA, reactive arthritis; IBS, irritable bowel syndrome.
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However, for the other pathogens we chose alternate methods, as
the number of registered deaths in the NMD was much lower than
reported in the published literature. We used data from the
Australian National Notiﬁable Disease Surveillance System
(NNDSS, 2001–10)34 to estimate the number of notiﬁed cases of
Campylobacter and Salmonella in 2010, and multiplied this by the
case fatality rates for these pathogens used in a study of the burden
of food-borne diseases in the USA.6 The viral study pathogens are
not nationally notiﬁable in Australia, and so we applied population
mortality rates for rotavirus and norovirus reported in two German
studies to the 2010 Australian population.35,36
For mild AGE cases (pathogen-speciﬁc), we subtracted the sum
of outpatient, hospitalized, and fatal AGE cases from total AGE
cases for each pathogen. This ensured internal consistency in our
pathogen-speciﬁc estimates.
For rotavirus cases and deaths in a vaccinated population <5
years old, the estimated percentage reduction in rotavirus cases of
each severity as a result of vaccination37,38 was applied to the
estimated number of rotavirus cases among unvaccinated
children.
2.5. Disease sequelae
We estimated the sequela fraction (proportion of Campylobac-
ter or Salmonella AGE cases that develop relevant sequelae) and
the proportion of sequelae cases in each severity category from the
studies listed in Table 1. We estimated the number of all-cause GBS
cases based on a study reporting GBS incidence in Australia,39 and
the number of all-cause GBS deaths from the NMD (ICD-10 code
G61.0, 2000–2010), and multiplied these by the pathogen-fraction
derived from a systematic review of Campylobacter-associated
GBS.40 For non-fatal GBS, the severity groupings (mild, severe <50
years, and severe 50 years) and proportion of non-fatal GBS cases
in each severity group were derived from Dutch studies of the
burden of Campylobacter-associated disease.22,41 We estimated
the ReA fraction (proportion of Campylobacter or Salmonella AGE
cases that develop ReA) and severity of ReA from two Finnish
population-based studies.42,43 As these studies followed laborato-
ry-conﬁrmed AGE cases, we applied this ReA fraction to outpatientand hospitalized Campylobacter and Salmonella AGE cases. Finally,
we applied the IBS fraction from a meta-analysis of post-infectious
IBS studies to our total estimated Campylobacter or Salmonella
AGE cases.44
2.6. Disease duration
Average disease duration was estimated for each pathogen for
mild, outpatient, and hospitalized AGE and sequelae using the
studies listed in Table 1. Because many studies do not record
duration of AGE according to disease severity, we used a
combination of data sources, including raw data from Australian
registries and studies (e.g., the OzFoodNet national outbreak
register and the community-based Water Quality Study),23,45,46
estimates from published studies from Australia and Europe,21,47,48
and estimates used in other studies examining the burden of food-
borne disease.49,50 Disease durations for sequelae were derived
from Dutch studies of the burden of food-borne diseases.22,41,44We
chose data sources to include in our models based on the criteria
listed above.
2.7. Other DALY model input
Disability weights for mild, outpatient, and hospitalized
diarrhoea from the Global Burden of Disease 2010 study
(GBD2010) were used for all six AGE pathogens.51 Disability
weights for sequelae were derived from Dutch studies of the
burden of food-borne diseases.22,41,44 Average YLL for deaths due
to each pathogen were calculated from the NMD (1997–1998 to
2007–2008) using Australian cohort life expectancies for
1996 without discounting.52 To determine the average DALY/case,
we divided the DALY burden by the number of AGE cases for each
pathogen.
2.8. Age-speciﬁc inputs into DALY models
Rates of AGE are known to differ by age. Some data used to
estimate all-cause AGE cases were available for speciﬁc age-groups
(e.g., total AGE cases from the NGSII and hospitalizations),
while other data only had whole-population estimates available
K.B. Gibney et al. / International Journal of Infectious Diseases 28 (2014) 176–185180(e.g., emergency department encounters and deaths). Likewise,
pathogen fractions were often available for speciﬁc age-groups,
however the age-groups used varied by study. Where available,
age-group speciﬁc data were used in our calculations and data
stratiﬁed by age and then aggregated up to a total. However, we
have reported our results for the whole population and not for
speciﬁc age-groups.
2.9. Statistical analysis
Single input values were used to obtain the point estimate for
the number of cases and deaths, DALY, and DALY/case estimates.
These single input values were considered the ‘most likely’ values,
based on assessment of the quality and recency of the study from
which the values were derived and generalizability of results to the
Australian population. In addition, Monte Carlo analyses (10 000
iterations) using PERT (Project Evaluation and Review Techniques)
distributions were used to calculate 95% credible intervals (95%
CrI) for DALY/case estimates. Minimum, mode, and maximum
values used in the PERT distributions, along with the data sources
and approaches to calculate these, are included in the Supple-
mentary Material.
3. Results
We estimated 16 626 069 cases of AGE in Australia in 2010
(total population 22 million persons12), of which 26.6% were
attributed to one of norovirus, rotavirus, Cryptosporidium,
Giardia, Salmonella, and Campylobacter. The greatest numbers
of cases were caused by norovirus (2 180 145, 13.1% of all-cause
AGE cases), Campylobacter (774 003 cases, 4.7%), and Giardia
(614 740 cases, 3.7%) (Table 2). Rotavirus was estimated to cause
592 745 AGE cases in the total population (unvaccinated), of
which 223 370 (37.7%) cases were among unvaccinated children
<5 years old.
The proportion of all-cause AGE cases that were mild was
91.4%, outpatient was 8.1%, and hospitalized was 0.6%, but the
proportion of cases in each severity category varied between
pathogens (Table 2). The proportion of total AGE cases that wereTable 2
Estimating the burden of acute gastroenteritis (AGE) in Australia, 2010—number of cas
Number of cases 
AGE (population) Total Mild Outpatient 
No. (% of all-cause) No. (% of total) No. (% of total) 
All-cause AGE 16 626 069 (100) 15 192 016 (91.4) 1 339 866 (8.1)
Norovirus AGE 2 180 145 (13.1) 2 010 290 (92.2) 157 081 (7.2)
Rotavirus AGE
All ages, no vaccine 592 745 (3.6) 502 808 (84.8) 60 396 (10.2
<5 years, no vaccine 223 370 - 169 149 (75.7) 34 557 (15.5
<5 years, vaccinated 78 180 - 61 367 (78.5) 12 095 (15.5
Cryptosporidium AGE 195 495 (1.2) 168 107 (86.0) 24 105 (12.3
Giardia AGE 614 740 (3.7) 556 642 (90.5) 56 981 (9.3)
Campylobacter AGE 774 003 (4.7) 621 676 (80.3) 140 047 (18.1
Salmonella 71 255 (0.4) 14 697 (20.6) 46 726 (65.6
Sequelae (pathogen) Total (% AGE
cases)
Mild Outpatien
IBS (Campylobacter) 68 112 (8.8) - - - 
IBS (Salmonella) 6 270 (8.8) - - - 
ReA (Campylobacter) 11 252 (1.5) 8 751 (77.8) 2 250 
ReA (Salmonella) 2 505 (3.5) 1 592 (63.6) 763 
Total Mild Severe, <50
years
GBS (Campylobacter) 102 (0.01) 17 (16.7) 39 (39.0) 
37.1 years 14.2
IBS, irritable bowel syndrome; ReA, reactive arthritis; GBS, Guillain–Barre´ syndrome.mild ranged from 20.6% (Salmonella) to 92.2% (norovirus).
Salmonella had the highest proportion of outpatient (65.6%),
hospitalized (13.7%), and fatal AGE (case fatality rate 126/
100 000 AGE cases); therefore, Salmonella caused the fewest
AGE cases (71 255) but the most AGE fatalities (90). Conversely,
Giardia and Cryptosporidium were estimated to cause no deaths
in Australia in 2010.
For sequelae, it was estimated that IBS was most common
(68 112 Campylobacter-associated and 6270 Salmonella-associ-
ated cases), followed by ReA (11 252 and 2505 cases, respectively)
and GBS (102 Campylobacter-associated cases). Of these sequelae,
only GBS was estimated to cause fatalities (three deaths). The
average duration of AGE was shortest for the viral and longest for
the protozoal pathogens studied (Table 2). The average duration of
sequelae was shortest for ReA (0.6 years), followed by IBS
(5 years), while symptoms of GBS were estimated to persist
lifelong. Average YLL per AGE death ranged from 7.1 years
(norovirus) to 31.9 years (rotavirus, total population) and
82.6 years (rotavirus, children <5 years).
The DALY burden was greatest for the bacterial pathogens,
followed by viral and then protozoal pathogens (Figure 3).
Campylobacter was estimated to cause 18 222 DALYs at an
average of 23.5 DALY/1000 cases and Salmonella caused
3856 DALYs at an average of 54.1 DALY/1000 cases (Table 3).
Rotavirus was more severe among children than adults (average
4.2 DALY/1000 cases among unvaccinated children vs. 2.5 DALY/
1000 cases among the total unvaccinated population), and
rotavirus vaccine not only reduced the number of cases among
children (223 370 to 78 180), but also the average burden of each
rotavirus AGE case (4.2 to 1.6 DALY/1000 cases). Approximately
half the pathogen-speciﬁc DALY was due to mild AGE for
norovirus and Giardia, outpatient AGE for Cryptosporidium,
and fatal AGE for Salmonella (Figure 4). The combined DALY for
the six pathogens studied was 25 952, of which 70% was
attributable to Campylobacter (including 55% attributed to
Campylobacter-associated IBS) and 12% to deaths following
Campylobacter or Salmonella AGE. Ranking of the six gastroin-
testinal pathogens by different burden of disease metrics is shown
in Table 4.es and deaths, illness duration, and years of life lost (YLL)
Deaths Illness duration YLL
Hospitalized (Number per
100 000cases)
Mild Outpatient Hospitalized
No. (% of total)
 94 128 (0.6) 61a (0.4) 14.1
 12 757 (0.6) 17 (0.8) 2.1 days 2.4 days 7.2 days 7.1
) 29 521 (5.0) 20 (3.4) 4.9 days 7.1 days 7.7 days 31.9
) 19 657 (8.8) 7 (3.0) 4.9 days 7.1 days 7.7 days 82.6
) 4 718 (6.0) 0 (0.0) 4.9 days 7.1 days 7.7 days -
) 3 283 (1.7) 0 (0.0) 4.0 days 12.5 days 21.4 days -
 1 117 (0.2) 0 (0.0) 5 days 15 days 33 days -
) 12 228 (1.6) 52 (6.7) 3.5 days 9.7days 14.4 days 19.2
) 9 742 (13.7) 90 (126.3) 2.5 days 6 days 12 days 22.6
t Hospitalized Deaths All cases YLL
- - - 0 (0.0) 5 years -
- - - 0 (0.0) 5 years -
(20.0) 250 (2.2) 0 (0.0) 0.6 years -
(30.5) 149 (6.0) 0 (0.0) 0.6 years -
Severe, 50
years
Deaths Acute (clinical)
phase
Chronic
phase
YLL
44 44.1 3 (0.4) 1 year
Figure 3. Disability adjusted life years (DALY) burden of six pathogens causing
acute gastroenteritis (AGE), including contribution of different disease severity
states and sequelae—Australia, 2010.
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We have documented the estimated disease burden in Australia
2010 attributable to six gastrointestinal pathogens using a number
of metrics, including number of AGE cases, number of AGE
fatalities, and DALYs. The pathogen with the greatest disease
burden varied according to the metric used: norovirus caused the
most cases (2 180 145), Salmonella the most fatalities (90), and
Campylobacter with sequelae the most DALYs (18 222). Salmonel-
la- and Campylobacter-associated sequelae, particularly Campylo-
bacter-associated IBS, dominated the combined DALY estimates for
the selected pathogens, while deaths associated with these two
bacterial pathogens also had a signiﬁcant impact. Therefore,
preventing cases of Campylobacter and Salmonella would have a
signiﬁcant public health impact in Australia, and as food-borneTable 3
Annual burden of selected pathogens causing acute gastroenteritis (AGE), Australia, 20
Pathogen Sequelae/population AGE cases A
(Number per
1000 population)
(
m
p
Campylobacter Nil 774 003 (34.7) 5
GBS, ReA 
GBS, ReA, IBS 
Salmonella Nil 71 255 (3.2) 9
ReA 
ReA, IBS 
Rotavirus Nil
All, unvaccinated 592 745 (26.5) 2
<5 years of age, unvaccinated 223 370 (152.9) 
<5 years of age, vaccinated 78 180 (53.5) 
Norovirus Nil 2 180 145 (97.6) 1
Giardia Nil 614 740 (27.5) 
Cryptosporidium Nil 195 495 (8.8) 
DALY, disability-adjusted life years; CrI, credible interval; GBS, Guillain–Barre´ syndromtransmission is signiﬁcant for both,4,6,53 optimizing food safety
could signiﬁcantly reduce the overall gastrointestinal disease
burden. Additionally, these results support the need for further
research into the pathogenesis, prevention, and management of
post-infectious IBS to reduce the burden of AGE-associated disease
in developed countries.
DALY models provide information that is lacking in estimates of
disease cases and deaths. Using AGE case numbers to determine
disease burden ignores differences in disease severity between
pathogens. For example, although norovirus AGE cases are
common, disease was often mild, fatalities were rare and occurred
among the elderly, and illness duration was short, so the average
DALY/case for norovirus was low. Using the number of deaths to
demonstrate disease burden provides information about the most
severe AGE cases, however information about morbidity is lacking.
We estimated no deaths due to Giardia or Cryptosporidium, so
their burden would be overlooked if only deaths were considered.
In addition to number of AGE cases and deaths, DALY models
incorporate information on different disease outcomes including
sequelae, disease duration, disease severity (disability weights),
and age at death. Furthermore, DALY/case estimates provide
information about the severity of an average case of disease caused
by each pathogen. Our disease models additionally demonstrate
the contribution of different disease outcomes to the overall
disease burden for each pathogen.
The six study pathogens were chosen as the most important in
the three major pathogen groups (viral, protozoal, and bacterial) in
high-income countries. Although the six study pathogens cause
signiﬁcant disease burden in developing countries, there are
differences in AGE aetiology between high- and low-income
countries. For example, in a prospective study of children in Africa
and Asia, the four pathogens causing the most moderate-to-severe
AGE cases were rotavirus, Cryptosporidium, enterotoxigenic
Escherichia coli producing heat-stable toxin (ST-ETEC), and
Shigella.54 Therefore, the relative contribution of different patho-
gens to the overall AGE disease burden may differ substantially
between high- and low-income countries. This highlights the need
for country- or region-speciﬁc data when estimating pathogen-
speciﬁc disease burden. Similarly, this study addresses the disease
burden of study pathogens within the total Australian population
and does not examine the burden among subpopulations. It would
be interesting, but beyond the scope of the current study, to
compare the burden of the study pathogens between indigenous
and non-indigenous Australians; these results could be used to
tailor public health interventions to the indigenous context. For10—number of cases and deaths, DALY, and DALY/case
GE deaths DALY DALY/1000 cases
Number per
illion
opulation)
(Number per
100 000
population)
Point estimate PERT distribution
Mean 95% CrI
2 (2.3) 2 242 (10.0) 2.9 3.0 2.0–4.2
3 918 (17.5) 5.1 5.3 4.1–6.7
18 222 (81.6) 23.5 25.9 10.7–43.6
0 (4.0) 2 285 (10.2) 32.1 34.9 13.8–57.4
2 539 (11.4) 35.6 39.5 18.3–62.4
3 856 (17.3) 54.1 59.8 32.2–88.0
0 (0.9) 1 465 (6.6) 2.5 2.2 1.8–2.5
7 (4.5) 936 (64.1) 4.2 4.0 3.2–4.5
0 (0.0) 126 (8.6) 1.6 1.5 1.3–1.7
7 (0.8) 1 109 (5.0) 0.5 0.6 0.4–0.8
0 (0.00) 967 (4.3) 1.6 1.7 1.1–2.8
0 (0.0) 333 (1.5) 1.7 2.0 1.5–3.0
e; ReA, reactive arthritis; IBS, irritable bowel syndrome.
Figure 4. Relative contribution of disease severity states and sequelae to disability-adjusted life years (DALY) for six pathogens causing acute gastroenteritis (AGE)—Australia,
2010.
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higher among indigenous compared to non-indigenous Australians
and this gap has widened following vaccine introduction in 2007,
possibly due to lower vaccine coverage among indigenous children
and lower vaccine effectiveness against circulating rotavirus
genotypes.55
Consistent with other studies that have failed to identify a
pathogen for a majority of AGE cases, our six study pathogens
accounted for 27% of the estimated number of all-cause infectious
AGE cases in Australia in 2010. In a recent UK study, no pathogen
was identiﬁed among 64% of mild AGE cases and 52% of outpatient
AGE cases >5 years of age despite extensive testing.20 Likewise,
only 21% of AGE cases in the USA could be attributed to 24 known
gastrointestinal pathogens.56 Therefore, it is currently not possible
to account for all AGE cases in pathogen-speciﬁc disease models.
The choice of AGE sequelae in disease models has the potential
to dramatically impact DALY estimates. Based on our interpreta-
tion of available data, we incorporated GBS, ReA, and IBS into our
Campylobacter disease model and ReA and IBS into our Salmonella
disease model; however, other burden-of-disease studies have
included different sequelae.4,57,58 To facilitate comparison with
other disease burden studies, we have clariﬁed the contribution of
each sequela to our DALY estimates and have provided results for
Salmonella and Campylobacter with and without sequelae.
Comparing DALY results between studies is also affected by
the inconsistent use of YLL discounting, disability weights, diseaseTable 4
Ranking of gastrointestinal pathogens using different burden of disease metrics,
Australia 2010a
Rank No. AGE cases No. deaths DALY DALY/case
1 Norovirus Salmonella Campylobacter Salmonella
2 Campylobacter Campylobacter Salmonella Campylobacter
3 Giardia Rotavirus Rotavirus Rotavirus
4 Rotavirus Norovirus Norovirus Cryptosporidium
5 Cryptosporidium Giardia/
Cryptosporidium
Giardia Giardia
6 Salmonella Cryptosporidium Norovirus
AGE, acute gastroenteritis; DALY, disability-adjusted life years.
a Rotavirus burden calculated using the non-vaccinated Australian population;
however rotavirus vaccine was introduced for Australian infants in mid-2007.incidence, and duration estimates. For example, we used disability
weights for AGE from the recently published GBD2010 study,51
although the GBD2010 study deﬁned AGE categories in terms of
symptoms rather than healthcare-seeking behaviours as used in
our study and most prior DALY studies of AGE.4,9,58,59 Available
data necessitated the use of healthcare-seeking behaviours rather
than symptoms to classify mild, outpatient, and hospitalized AGE
cases, however we believe that these criteria would roughly
approximate the symptom-based categories of mild, moderate,
and severe diarrhoea used in the GBD2010 study. The Burden of
Disease and Injury in Australia 2003 study estimated the overall
burden of diarrhoeal disease at 1858 DALYs,59 much lower than
our AGE DALY estimates. This is partly because they applied a
discount rate of 3% to YLL estimates, did not include sequelae, and
had different estimates for the proportion of cases requiring
hospitalization and disease duration. Our DALY/1000 cases
estimate for Salmonella was similar to a recent Dutch food-borne
disease study (54.1 vs. 49), but our DALY/1000 cases estimate for
Campylobacter was lower (23.5 vs. 41).4 Conversely, our annual
DALY/100 000 population estimate was higher for both Salmonella
(17.3 vs. 7.7) and Campylobacter (81.6 vs. 20) than the Dutch study
due to our higher estimated incidence of these diseases.
Interestingly, the relative ranking of pathogens according to
burden also differed between studies, with norovirus causing a
greater DALY burden than Salmonella in Dutch and New Zealand
food-borne disease studies, and Salmonella a greater quality-
adjusted life years (QALY) loss than both Campylobacter and
norovirus in a food-borne disease study in the USA.57 Finally, our
DALY/1000 cases estimate for rotavirus among unvaccinated
children was much lower than a previous Australian estimate
(4.2 vs. 13/1000 cases),9 largely due to the reduction in estimated
deaths when using data from Australia and other developed
countries compared to estimates including developing countries
with worse health outcomes. This highlights the beneﬁts of using
targeted, region-speciﬁc data sources.
Rotavirus vaccination has been available free of charge as part
of Australia’s National Immunisation Program since July 2007.10 By
the start of 2010, Australian children up to the age of 2.5 years
would have been eligible for vaccination. Because data post-
vaccination are limited, we presented our estimates for rotavirus
burden among unvaccinated Australians but acknowledge this
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tion reduces AGE cases, severity, and fatalities.10 As further data
become available, our rotavirus disease models could be used to
quantify the reduction in DALY burden attributable to rotavirus
vaccination in Australia.
Among our included pathogens, Salmonella stood out for
having a high DALY/case. We estimated the incidence of
Salmonella AGE to be 3.2/1000 person-years, which is similar to
some previous estimates for Australasia and North America (2.5–
6.9),60–62 and our estimate of 71 255 Salmonella AGE cases in
Australia in 2010 is in keeping with previous Australian estimates
(49 843–92 000).7,53 Our estimate that 65.6% of Salmonella AGE
cases were outpatient cases exceeds studies from the USA and the
Netherlands (12.3–15.4%),49,62 however is similar to a UK study of
food-borne disease (71.4%),63 while our estimate that 13.7% of
Salmonella AGE cases were hospitalized cases exceeds the other
studies mentioned (1.1–3.6%), possibly due to our inclusion of half
the non-admitted ED presentations in the hospitalized AGE
category. Finally, although our case fatality rate for Salmonella
(126/100 000 AGE cases) exceeds our estimates for the other
pathogens studied (0–6.7/100 000), it is similar to recent estimates
from Australasia and the Netherlands (114–152/100 000).4,60
The reliance on multiple datasets for our estimates is an
acknowledged limitation. As highlighted by our Salmonella model,
using multiple data sources to estimate numbers of AGE cases and
deaths can result in apparent discrepancies within and between
disease models. For fatal AGE cases we used different approaches
as well as different data sources, resulting in our estimated number
of fatal AGE cases caused by Campylobacter and Salmonella
exceeding our estimated number of all-cause fatal AGE cases. NMD
ﬁgures were used to estimate all-cause AGE mortality and these
likely signiﬁcantly underestimate deaths attributable to AGE due
to under-diagnosis and under-reporting. Australian notiﬁcation
data have recently been used to estimate the number of food-borne
Salmonella and Campylobacter AGE cases and these estimates
were lower than ours.64
While an attempt has been made to include the most relevant
high-quality data in the DALY/case models, inevitably the quality
of input data varied across the models. We used results from the
NGSII-2008 study to estimate the number of all-cause AGE in
Australia.65 Potential problems with the NGSII-2008 study include
an unrepresentative sample of respondents (only those with a
landline telephone were called, and of those contacted only 49%
participated in the survey) and poor recall over a 4-week period.
AGE rates estimated from retrospective surveys tend to be lower
when the recall period is 4 weeks compared to 1 week,20,66,67 while
in a UK study, AGE rates calculated using a prospective cohort
study design were lower than those obtained using a retrospective
telephone survey design.20 Although study design can impact
estimated AGE rates, the NGSII-2008 study was designed to mirror
the earlier national gastroenteritis survey and the estimated AGE
rates were similar to international estimates.2,68,69 Heterogeneity
in data sources used could account for some of the apparent
differences in pathogen-speciﬁc estimates presented in this study.
However, we attempted to identify the most credible data source
for each data point, which resulted in the use of different data
sources within and between pathogen disease models. Differences
in study design, including inconsistencies in laboratory techniques
used to detect faecal pathogens, made pooling or meta-analysis of
the results from different studies inappropriate. Monte Carlo
simulations were performed to indicate the precision of the DALY/
case point estimates.
In conclusion, we have estimated the burden of disease due to
selected gastrointestinal pathogens using a number of metrics,
including number of AGE cases, number of AGE fatalities, and
DALYs. The pathogen with the greatest disease burden variedaccording to the metric used: norovirus caused the most cases,
Salmonella the most fatalities, and Campylobacter with sequelae
the greatest DALY burden. We believe DALYs provide the most
meaningful measure of disease burden as they incorporate
information about both morbidity and mortality. We have built
disease models that can easily be updated as new data become
available, including changes in case numbers and deaths due to
public health interventions. These results can help prioritize and
measure the impact of public health interventions and can be
translated to other, similar, populations.
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